Neuromuscular Diseases:

Improving Outcomes through Optimal Diagnosis and Emerging Targeted Therapies

This Learning Center is a free educational platform designed for neurologists, neuromuscular specialists, and other clinicians involved in the identification and management of patients with amyotrophic lateral sclerosis (ALS), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Our goal is to ensure that you—the practicing clinician—have access to the latest information and resources related to the diagnosis, current treatment, and emerging treatment strategies for these patients.

We encourage you to share this educational resource with your colleagues and your healthcare team.


Amyotrophic Lateral Sclerosis: New Approaches to Diagnosis and Treatment

Credit Available: 1.00 AMA PRA Category 1 credit(s)

In this activity, expert Stanley H. Appel, MD, will offer learners a comprehensive understanding of ALS, including its natural history, epidemiology, clinical features, and differential diagnosis. Subsequently, Dr. Appel will discuss the latest emerging treatment strategies for ALS, specifically highlighting the newest therapeutic modalities that target key pathways involved in ALS pathogenesis, including Treg-based therapy, nucleic acid-based therapy, and receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibition. Clinical case vignettes will be used to reinforce the practical application of the latest diagnostic criteria for ALS, as well as the innovative therapies discussed during the session.

Chronic Inflammatory Demyelinating Polyneuropathy: A Challenging but Treatable Condition

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Join expert Richard A. Lewis, MD, as he takes learners on a deep dive into CIDP, exploring its etiology, pathogenesis, and clinical presentation. Through clinical case vignettes, Dr. Lewis will guide learners through the diagnosis of CIDP, covering topics such as the differences between typical and atypical variants of CIDP, as well as the similarities and differences between CIDP and Guillain-Barré syndrome. Finally, Dr. Lewis will discuss the latest management strategies for CIDP, providing valuable insights into emerging therapies such as C1s-targeted therapy, neonatal Fc receptor antagonists, and anti-CD20 therapy, and how they may significantly improve the management of this debilitating disease.

Improving Outcomes in Myasthenia Gravis: Latest Updates in Diagnosis and Treatment

Credit Available: 1.00 AMA PRA Category 1 credit(s)

Led by expert Srikanth Muppidi, MD, this activity will provide learners with an in-depth understanding of MG. Dr. Muppidi will begin by covering essential topics, such as MG pathophysiology, subtyping, and differential diagnosis. He will then delve into current paradigms of care for MG, including treatment algorithms based on serology, and present the latest efficacy and safety data on recently approved therapies. Dr. Muppidi will also provide an overview of emerging therapy options that may improve patient outcomes. Case vignettes will be used to offer learners the opportunity to explore the practical application of the latest treatment approaches and gain a deeper understanding of how to provide optimal care for patients with MG.